HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines.

MLA

McLemore, Lauren E., et al. “HER2 Testing in Breast Cancers: Comparison of Assays and Interpretation Using ASCO/CAP 2013 and 2018 Guidelines.” Breast Cancer Research & Treatment, vol. 187, no. 1, May 2021, pp. 95–104. EBSCOhost, https://doi.org/10.1007/s10549-021-06208-5.

APA

McLemore, L. E., Albarracin, C. T., Gruschkus, S. K., Bassett, R. L., Wu, Y., Dhamne, S., Yim, I., Lin, K., Bedrosian, I., Sneige, N., & Chen, H. (2021). HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines. Breast Cancer Research & Treatment, 187(1), 95–104. https://doi.org/10.1007/s10549-021-06208-5

Chicago

McLemore, Lauren E., Constance T. Albarracin, Stephen K. Gruschkus, Roland L. Bassett, Yun Wu, Sagar Dhamne, Isaiah Yim, et al. 2021. “HER2 Testing in Breast Cancers: Comparison of Assays and Interpretation Using ASCO/CAP 2013 and 2018 Guidelines.” Breast Cancer Research & Treatment 187 (1): 95–104. doi:10.1007/s10549-021-06208-5.